Saroj Brar, MD
Psychiatry · Cleveland, OHNPI 1487733366
Payments from drug & device makers
Across 331 payments — averaging $65.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$8K
- Alkermes, Inc.$3K
- Johnson & Johnson$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Sunovion Pharmaceuticals Inc.$1K
- plus $4K from 13 others
What the payments were for
- Food & beverage$12,87198%
- Education$2132%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 2 | $8,480 |
| Alkermes, Inc. | 71 | $2,759 |
| Johnson & Johnson | 40 | $2,449 |
| Teva Pharmaceuticals USA, Inc. | 37 | $1,500 |
| Otsuka America Pharmaceutical, Inc. | 36 | $1,394 |
| Sunovion Pharmaceuticals Inc. | 39 | $1,207 |
| AbbVie(2 entities) | 25 | $987 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 23 | $974 |
| E.r. Squibb & Sons, L.L.C. | 16 | $746 |
| Neurocrine Biosciences, Inc. | 16 | $314 |
| Vanda Pharmaceuticals Inc. | 8 | $233 |
| Tempus AI, Inc | 2 | $135 |
| Indivior Inc. | 6 | $124 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $102 |
| Axsome Therapeutics, Inc. | 3 | $75 |
| Lundbeck LLC | 2 | $31 |
| Luye Pharma (USA) Ltd. | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$2,452
- LYBALVI$1,850
- INVEGA SUSTENNA$1,136
- VRAYLAR$719
- INVEGA TRINZA$669
- LATUDA$668
- CAPLYTA$614
- ARISTADA INITIO$613
- COBENFY$586
- ABILIFY MAINTENA$464
- UZEDY$355
- AUSTEDO$349
- REXULTI$342
- Austedo XR$246
- SPRAVATO$243
- INGREZZA$125
- Fanapt$118
How this compares
$21,564 in reported general payments places this provider in the 90th percentile of 1,119 psychiatry providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 311 | $878,601 |
| AristadaAripiprazole Lauroxil | 106 | $311,097 |
| IngrezzaValbenazine Tosylate | 31 | $238,707 |
| LybalviOlanzapine/Samidorphan Malate | 112 | $178,822 |
| Invega TrinzaPaliperidone Palmitate | 15 | $104,330 |
| PerserisRisperidone | 25 | $70,477 |
| Abilify MaintenaAripiprazole | 25 | $68,187 |
| CaplytaLumateperone Tosylate | 35 | $56,319 |
| VraylarCariprazine Hcl | 22 | $30,153 |
| Clozapine | 253 | $26,361 |
| RexultiBrexpiprazole | 13 | $19,075 |
| Divalproex Sodium ErDivalproex Sodium | 261 | $15,345 |
| Lurasidone Hcl | 196 | $13,203 |
| Paliperidone ErPaliperidone | 54 | $10,982 |
| Haloperidol Decanoate | 225 | $10,562 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $2,449 | $982,931326 claims |
| Alkermes, Inc.Aristada, Lybalvi | $2,759 | $489,919218 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $314 | $238,70731 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,394 | $87,26238 claims |
| Indivior Inc.Perseris | $124 | $70,47725 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $974 | $56,31935 claims |
| AbbVieVraylar | $987 | $30,15322 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $1,500 | $1,35532 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,119 psychiatry providers in Ohio.
Other psychiatry in Cleveland
- Binit ShahCleveland$913K
- Rajeet ShresthaCleveland$537K
- Martha SajatovicCleveland$404K
- Joseph CalabreseCleveland$82K
- Ketan DeorasCleveland$80K
- Keming GaoCleveland$76K
- Aaron VazquezCleveland$55K
- Shishuka MalhotraCanton$15M
- Henry NasrallahCincinnati$3.8M
- Otto DuenoDayton$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.